Merck touts PhIII data burnishing $500M platform — what kind of bar does it set for a chronic cough drug?
Roy Baynes surprised some analysts during Merck’s investor day last June — its first in five years — when he shone a surprising spotlight on gefapixant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
